{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:29:21Z","timestamp":1794475761562,"version":"4.9.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["UH3AI133675"],"award-info":[{"award-number":["UH3AI133675"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006462","name":"City University of New York","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006462","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128666","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:56:34Z","timestamp":1778241394000},"page":"128666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effect of a third COVID-19 vaccine dose on the incidence of Long COVID among adults who completed a primary vaccine series: a target trial emulation in a community-based cohort"],"prefix":"10.1016","volume":"84","author":[{"given":"Yanhan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zach","family":"Shahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKaylee M.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Gebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128666_bb0005","series-title":"Long COVID basics","author":"CDC","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128666_bb0010","article-title":"National academies of sciences, engineering, and medicine committee on examining the working definition for Long covid. Long COVID defined","author":"Ely","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128666_bb0015","series-title":"A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences","author":"National Academies of Sciences, Engineering, and Medicine","year":"2024"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128666_bb0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.51151","article-title":"Prevalence of post-COVID-19 condition and activity-limiting post-COVID-19 condition among adults","volume":"7","author":"Vahratian","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128666_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1165611","article-title":"The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies","volume":"11","author":"Xu","year":"2023","journal-title":"Front Public Health"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128666_bb0030","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/jmv.27697","article-title":"Current evidence on efficacy of COVID-19 booster dose vaccination against the omicron variant: a systematic review","volume":"94","author":"Chenchula","year":"2022","journal-title":"J Med Virol"},{"issue":"100451","key":"10.1016\/j.vaccine.2026.128666_bb0035","article-title":"Reported effectiveness of COVID-19 monovalent booster vaccines and hybrid immunity against mild and severe omicron disease in adults: a systematic review and meta-regression analysis","volume":"17","author":"Nealon","year":"2024","journal-title":"Vaccine X"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128666_bb0040","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.vaccine.2024.04.049","article-title":"A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against omicron variants","volume":"42","author":"Song","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128666_bb0045","article-title":"Relative effectiveness of bivalent COVID-19 vaccine: a systematic review and meta-analysis","volume":"10","author":"Cheng","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128666_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2515","article-title":"Immunogenicity, clinical efficacy and safety of additional second COVID-19 booster vaccines against Omicron and its subvariants: a systematic review","volume":"34","author":"Chenchula","year":"2024","journal-title":"Rev Med Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128666_bb0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2213-2600(23)00414-9","article-title":"The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia","volume":"12","author":"Catal\u00e0","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2026.128666_bb0060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbi.2023.03.022","article-title":"COVID-19 vaccination for the prevention and treatment of long COVID: a systematic review and meta-analysis","volume":"111","author":"Ceban","year":"2023","journal-title":"Brain Behav Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128666_bb0065","article-title":"Long COVID prevalence and the impact of the third SARS-CoV-2 vaccine dose: a cross-sectional analysis from the third follow-up of the Borriana cohort, Valencia, Spain (2020\u22122022)","volume":"11","author":"Dom\u00e8nech-Montoliu","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128666_bb0070","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/vaccines12060688","article-title":"COVID-19 booster vaccination status and long COVID in the United States: a nationally representative cross-sectional study","volume":"12","author":"Romeiser","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128666_bb0075","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1016\/j.vaccine.2024.04.070","article-title":"COVID-19 booster vaccine uptake and reduced risks for long-COVID: a cross-sectional study of a U.S. adult population","volume":"42","author":"Xie","year":"2024","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128666_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s41687-023-00616-5","article-title":"Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during omicron","volume":"7","author":"Di Fusco","year":"2023","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.vaccine.2026.128666_bb0085","article-title":"Booster vaccination and post COVID-19 condition during the Omicron variant-dominant wave: a large population-based study","author":"Iba","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128666_bb0090","article-title":"Association between COVID-19 booster vaccination and COVID-19 outcomes among U.S. adults","volume":"12","author":"Nguyen","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128666_bb0095","article-title":"Bivalent boosters and risk of post-acute sequelae following vaccine-breakthrough SARS-CoV-2 Omicron infection: a cohort study","author":"Wee","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128666_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281429","article-title":"Post COVID-19 condition after wildtype, Delta, and omicron SARS-CoV-2 infection and prior vaccination: pooled analysis of two population-based cohorts","volume":"18","author":"Ballouz","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128666_bb0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/cid\/ciad143","article-title":"Post-acute sequelae after severe acute respiratory syndrome coronavirus 2 infection by viral variant and vaccination status: a multicenter cross-sectional study","volume":"77","author":"Kahlert","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128666_bb0110","series-title":"CHASING COVID cohort study","year":"2024"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128666_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-048778","article-title":"Cohort profile: a national, community-based prospective cohort study of SARS-CoV-2 pandemic outcomes in the USA\u2014the CHASING COVID cohort study","volume":"11","author":"Robertson","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128666_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-51029-9","article-title":"Seroincidence of SARS-CoV-2 infection prior to and during the rollout of vaccines in a community-based prospective cohort of U.S. adults","volume":"14","author":"Nash","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128666_bb0125","article-title":"SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults","author":"Nash","year":"2021","journal-title":"medRxiv"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128666_bb0130","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jmv.26303","article-title":"Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies","volume":"93","author":"Tr\u00e9-Hardy","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2026.128666_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104613","article-title":"Comparison of eight commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total antibody","volume":"132","author":"Trabaud","year":"2020","journal-title":"J Clin Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128666_bb0140","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/jalm\/jfab038","article-title":"Evaluation of the clinical performance of 7 serological assays for SARS-CoV-2 for use in clinical laboratories","volume":"6","author":"Plaga","year":"2021","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.vaccine.2026.128666_bb0145","series-title":"FDA approves first COVID-19 vaccine","author":"Office of the Commissioner","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128666_bb0155","unstructured":"U.S. fda grants emergency use authorization for Novavax COVID-19 vaccine, Adjuvanted for individuals aged 18 and over. 2025 Accessed January 4, 2025. https:\/\/ir.novavax.com\/press-releases\/2022-07-13-U-S-FDA-Grants-Emergency-Use-Authorization-for-Novavax-COVID-19-Vaccine,-Adjuvanted-for-Individuals-Aged-18-and-Over."},{"key":"10.1016\/j.vaccine.2026.128666_bb0160","series-title":"Coronavirus (COVID-19) update: FDA takes additional actions on the use of a booster dose for COVID-19 vaccines","author":"Office of the Commissioner","year":"2021"},{"issue":"45","key":"10.1016\/j.vaccine.2026.128666_bb0165","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.15585\/mmwr.mm7145a2","article-title":"Interim recommendations from the advisory committee on immunization practices for the use of bivalent booster doses of COVID-19 vaccines - United States, October 2022","volume":"71","author":"Rosenblum","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128666_bb0170","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","article-title":"A clinical case definition of post-COVID-19 condition by a Delphi consensus","volume":"22","author":"Soriano","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128666_bb0175","series-title":"COVID-19","article-title":"Clinical overview of Long COVID","author":"CDC","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128666_bb0180","doi-asserted-by":"crossref","DOI":"10.5888\/pcd13.160080","article-title":"Comparison of 2 disability measures, Behavioral Risk Factor Surveillance System, 2013","volume":"13","author":"Stevens","year":"2016","journal-title":"Prev Chronic Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128666_bb0185","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128666_bb0190","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128666_bb0195","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/EDE.0000000000001601","article-title":"Emulating target trials to avoid immortal time bias - an application to antibiotic initiation and preterm delivery","volume":"34","author":"Caniglia","year":"2023","journal-title":"Epidemiology"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128666_bb0200","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/sim.9718","article-title":"Causal inference in survival analysis using longitudinal observational data: sequential trials and marginal structural models","volume":"42","author":"Keogh","year":"2023","journal-title":"Stat Med"},{"issue":"50","key":"10.1016\/j.vaccine.2026.128666_bb0205","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.15585\/mmwr.mm7050e2","article-title":"Booster and additional primary dose COVID-19 vaccinations among adults aged \u226565 years - United States, August 13, 2021-November 19, 2021","volume":"70","author":"Fast","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128666_bb0210","doi-asserted-by":"crossref","unstructured":"Hedges L.V. Interpretation of the standardized mean difference effect size when distributions are not normal or homoscedastic. Educ Psychol Meas 2024. Published online October 6. 00131644241278928; 85 (2): 245-257.","DOI":"10.1177\/00131644241278928"},{"issue":"25","key":"10.1016\/j.vaccine.2026.128666_bb0215","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128666_bb0220","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128666_bb0225","series-title":"Causal Inference","author":"Hern\u00e1n","year":"2016"},{"key":"10.1016\/j.vaccine.2026.128666_bb0230","author":"Causal inference: What if (the book)"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128666_bb0235","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamainternmed.2023.0750","article-title":"Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis","volume":"183","author":"Tsampasian","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128666_bb0240","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.vaccine.2023.01.023","article-title":"COVID-19 booster vaccination uptake and infection breakthrough amongst health care workers in Wales: a national prospective cohort study","volume":"41","author":"Bedston","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128666_bb0245","doi-asserted-by":"crossref","unstructured":"Rane M.S., Shen Y., Robertson M.K., et al. Barriers to initial COVID-19 booster among U.S. adults who completed a primary vaccine series in the CHASING COVID cohort, September 2021\u2013October 2022. Am J Epidemiol 2024;kwae209. Published online July 16; 194 (5): 1341-1351.","DOI":"10.1093\/aje\/kwae209"},{"key":"10.1016\/j.vaccine.2026.128666_bb0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jclinepi.2017.11.021","article-title":"Electronic medical records can be used to emulate target trials of sustained treatment strategies","volume":"96","author":"Danaei","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128666_bb0255","author":"Bosworth"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128666_bb0265","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128666_bb0270","series-title":"COVID-19","article-title":"Staying up to date with COVID-19 vaccines","author":"CDC","year":"2024"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:58:59Z","timestamp":1794473939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26004743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"alternative-id":["S0264410X26004743"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128666","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of a third COVID-19 vaccine dose on the incidence of Long COVID among adults who completed a primary vaccine series: a target trial emulation in a community-based cohort","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128666","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128666"}}